Meetings
The HCV Forum convenes once a year to discuss emerging issues in the field of HCV drug development. See below for more information on the most recent HCV Forum meeting.
NOV-03-11 On November 3rd, the Forum held the 7th HCV DrAG Meeting in San Francisco, in conjunction with the 62nd American Association for the Study of Liver Diseases (AASLD*) meeting "Issues in HCV Clinical Trials" focused on HCV viral load assays (LOD/LLOQ), as well as trials in current drug users and patients on opiate substitution therapy. With 72 people in attendance representing regulatory agencies, industry, academia, treatment, and advocacy, the panels had lively and productive discussions. In addition to spurring interest in special populations such as bleeding disorder and opiate substitution patients, the seventh HCV DrAG Meeting appears to have brought consensus on the HCV viral load cut-off and reporting, both of which will be used in trials and will translate into practice.
*This is not an official function/event of the American Association for the Study of Liver Diseases
Read more »
|
|